Keyphrases
Neuroendocrine Prostate Cancer
66%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
45%
Prostate Cancer Patients
44%
RET Kinase
36%
Patient-derived Xenograft
36%
Vulnerability
33%
ZBTB7A
33%
C-Cbl
33%
B7-H3
33%
Molecular Analysis
33%
Myeloid Cells
33%
Rapid Degradation
33%
Phosphorylation Targets
33%
Global Phosphoproteome
33%
Global Proteomics
33%
Patient-derived Tumor Xenograft
33%
Androgen Receptor
25%
Macrophages
25%
Src Kinase
25%
Adenocarcinoma
25%
Cell-type Specificity
16%
Mast Cells
16%
Rheostat
16%
Phosphopeptides
16%
Tumor
15%
Aggressive Variant Prostate Cancer
15%
Cancer Tumor
14%
Phosphoproteomics
11%
Small Cell Neuroendocrine
10%
Receptor-independent
10%
Neuroendocrine Phenotype
10%
Little-c
8%
Steady State
8%
Tyrosine Phosphorylation
8%
Phosphopeptide Analysis
8%
Cell Activation
8%
E3 Ubiquitin Ligase
8%
Immunoreceptor Tyrosine-based Activation Motif
8%
Ubiquitin-mediated Degradation
8%
Advanced Prostate Cancer
8%
Androgen Deprivation Therapy
8%
Clinically Significant
8%
Unique Proteins
8%
Biological Replicates
8%
Proteome
8%
Dissonance
8%
Interconversion
8%
Signaling Pathway
7%
Gene Network
7%
Prostate Cancer
7%
Biochemistry, Genetics and Molecular Biology
Androgen Receptor
83%
Phosphopeptide
44%
Cancer Cell
42%
Phosphotransferase
41%
Kinase
41%
Macrophage
33%
Myeloid
33%
Receptor Tyrosine Kinase
33%
Neuroendocrine Cell
33%
Proteome
33%
Phosphoproteome
33%
Cofactors
22%
Cell Specificity
22%
Mast Cell
22%
Genetics
17%
Metabolite
16%
Enzyme
16%
Messenger RNA
16%
Programmed Cell Death
16%
Tumor Progression
13%
Tyrosine
11%
Immunoreceptor Tyrosine-Based Activation Motif
11%
Gene Network
11%
PD-L1
11%
Epigenetics
11%
CD276
11%
Immune Checkpoints
11%
Promoter Region
11%
HOXB13
11%
Steady State
11%
FOXA1
11%
Enhancer Region
11%
Cell Activation
11%
Ubiquitin-Conjugating Enzyme
11%
CTLA-4
11%
Ubiquitin
11%
Enzalutamide
11%
Transdifferentiation
8%
Cell Cycle Progression
8%
RNA Sequencing
8%
Cell Cycle
8%
G1/S Transition
8%
Gene Expression
8%
Cell Growth
8%
Transcription Factors
8%
Carcinogenesis
8%
Cell Viability
6%
Phosphoproteomics
6%
Medicine and Dentistry
Prostate Cancer
100%
Androgen Receptor
40%
Phosphotransferase
36%
Castration Resistant Prostate Cancer
36%
Neoplasm
25%
Cancer Cell
10%
Cell Signaling Pathway
9%
Programmed Cell Death
6%
Prostate Specific Membrane Antigen
6%
CTLA-4
6%
Enhancer Region
6%
Promoter Region
6%
Programmed Death-Ligand 1
6%
Immunotherapy
6%
Enzalutamide
6%
Precision Oncology
6%
Prostate Cancer Cell Line
6%
Tumor Progression
5%
